Table 2.
Summary of clinical trials investigating the outcomes of different KRAS co-mutations.
| Study | Pts | KRAS status | Treatment | Endpoint | KRAS status | ||||
|---|---|---|---|---|---|---|---|---|---|
| Skoulidis et al. (110) | K-only | KP | KL | ICIs | K-only | KP | KL | ||
| 174 | 37% (64) | 32% (56) | 31% (54) | ORR (%) | 28.6 | 35.7 | 7.4 | ||
| PFS (months) | 2.7 | 3.0 | 1.8 | ||||||
| OS (months) | 16.1 | 16.0 | 6.4 | ||||||
| Skoulidis et al. (53) | KRAS MUT | KRAS-KEAP1 MUT | Sotorasib | KRAS MUT | KRAS-KEAP1 MUT | ||||
| 104 | 81% (84) | 19% (20) | ORR (%) | 44 | 20 | ||||
| Alessi et al. (111) | K-only | KS | ICIs | KS | K-only | ||||
| 176 | 90% (159) | 10% (17) | ORR (%) | 0 | 22.0 | ||||
| PFS (months) | 1.4 | 4.1 | |||||||
| OS (months) | 3.0 | 15.1 | |||||||
| Liu et al. (112) | K-only | KP | KS | Non-immunotherapy | K-only | KP | KS | ||
| 155 | 61% (94) | 33% (52) | 6% (9) | DFS (months) | 18.0 | 16.31 | 10.97 | ||
| OS (months) | 20.11 | 18.48 | 15.37 | ||||||
| ICIs | |||||||||
| 77 | 56% (43) | 32% (25) | 12% (9) | PFS (months) | 2.77 | 4.63 | 1.73 | ||
KRAS, kirsten rat sarcoma viral oncogene homolog; Pts, patients; KL, KRAS-STK11/LKB1 co-mutant; KP, KRAS-TP53 co-mutant; ORR, objective response rate; PFS, progression-free survival; OS, overall survival; MUT, mutation; KEAP1, Kelch-like ECH-associated protein 1; ICIs, immune checkpoint inhibitors; KS, KRAS-SMARCA4 co-mutant; DFS, disease-free survival.